share_log

Vertex Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

福泰制药 | 144：拟议出售证券

美股sec公告 ·  02/21 11:41
Moomoo AI 已提取核心信息
Vertex Pharmaceuticals Inc. officer Stuart A. Arbuckle is set to sell 3,603 shares of common stock on 02/21/2024, as per the latest filing. The shares, valued at approximately $1,519,637.31, were acquired on 02/20/2024 as performance shares, a form of compensation from the issuer. This transaction follows a recent history of sales by Arbuckle, who has sold 17,702 shares over the past three months, totaling roughly $7,259,002.96 in gross proceeds.
Vertex Pharmaceuticals Inc. officer Stuart A. Arbuckle is set to sell 3,603 shares of common stock on 02/21/2024, as per the latest filing. The shares, valued at approximately $1,519,637.31, were acquired on 02/20/2024 as performance shares, a form of compensation from the issuer. This transaction follows a recent history of sales by Arbuckle, who has sold 17,702 shares over the past three months, totaling roughly $7,259,002.96 in gross proceeds.
最新文件显示，Vertex Pharmicals Inc.高管斯图尔特·阿巴克尔定于2024年2月21日出售3,603股普通股。这些股票价值约1,519,637.31美元，于2024年2月20日作为绩效股票收购，这是发行人的一种薪酬。该交易遵循了Arbuckle最近的销售记录，该公司在过去三个月中已出售了17,702股股票，总收益约为7,259,002.96美元。
最新文件显示，Vertex Pharmicals Inc.高管斯图尔特·阿巴克尔定于2024年2月21日出售3,603股普通股。这些股票价值约1,519,637.31美元，于2024年2月20日作为绩效股票收购，这是发行人的一种薪酬。该交易遵循了Arbuckle最近的销售记录，该公司在过去三个月中已出售了17,702股股票，总收益约为7,259,002.96美元。
有用
没用

该公告为独立文件：

独立文件1

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息